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Abstract
Background: Microbial infections have been implicated in initiating and enhancing severity of autoimmune
diseases including the demyelinating disease multiple sclerosis (MS). Nevertheless, the incidence of both acute and
persisting viral infections without evidence of autoimmune sequelae suggests that this process is well controlled.
The conditions promoting or stemming self-reactive (SR) T cells following viral-induced tissue damage thus need to
be better defined. Using a non-fatal viral mouse model of encephalomyelitis associated with demyelination and
disability, yet ultimate clinical improvement, this study set out to monitor uptake and presentation of endogenous
myelin antigens, as well as induction and fate of SR T cells.
Methods: Activation and central nervous system (CNS) recruitment of myelin-specific CD4 T cells was analyzed by
flow cytometry during encephalomyelitis induced by a glia tropic murine coronavirus. Potential antigen-presenting
cells (APC) ingesting myelin were characterized by flow cytometry and their ability to activate SR T cells tested by
co-culture with carboxyfluorescein succinimidyl ester (CFSE)-labeled myelin-specific CD4 T cells. Endogenous SR T
cell kinetics was analyzed within both cervical lymph nodes and CNS by Enzyme-Linked ImmunoSpot (ELISPOT)
following viral infection.
Results: The data demonstrate the presence of APC capable of activating SR T cells in both draining lymph nodes
and the CNS temporally correlating with overt demyelination. While both the CNS-infiltrating myeloid population
and microglia ingested myelin, only CNS-infiltrating APC were capable of presenting endogenous myelin antigen to
SR T cells ex vivo. Finally, SR T cell activation from the endogenous T cell repertoire was most notable when
infectious virus was controlled and paralleled myelin damage. Although SR T cell accumulation peaked in the
persistently infected CNS during maximal demyelination, they were not preferentially retained. Their gradual
decline, despite ongoing demyelination, suggested minimal re-stimulation and pathogenic function in vivo
consistent with the lack of autoimmune symptoms.
Conclusions: The results demonstrate the potential for CNS tissue destruction to induce and recruit SR T cells to
the injury site and support a host suppressive mechanism limiting development of autoimmunity.
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Background
Multiple sclerosis (MS) is an autoimmune disease of the
central nervous system (CNS) characterized by demye-
lination, axonal loss, and increasing disability [1, 2].
While the etiology of MS remains unknown, various
genetic and environmental factors have been associated
with MS pathogenesis [3–5]. Among the environmental
cues, viral infections, most prominently Epstein-Barr
virus and human herpes virus type 6, have been linked
to initiation or progression of disease [4, 6–9]; however,
their causal nature remains unclear. Anti-viral antibodies
and viral antigens have been detected in brain and cere-
brospinal fluid of MS patients [10–12]. Nevertheless, ac-
tive virus replication has yet to be demonstrated in the
CNS of MS patients. By contrast, infections have even
been proposed to limit autoimmunity [13]. Indeed, the
decreased incidence of infectious diseases in the past de-
cades inversely correlates with an increased incidence of
autoimmune diseases, including MS [14]. For example,
viral infection in an animal model of type I diabetes pre-
vents disease development [15, 16]. Similarly, mice bred
under conventional conditions are less susceptible to
diabetes than mice bred in a pathogen-free environment
[14], supporting the concept that microbiome burden
may reduce the incidence of autoimmunity [17]. There-
fore, the role of viral infections in autoimmune diseases
is complex and remains largely elusive.
Activation of self-reactive (SR) immune cells by epi-
tope spreading, molecular mimicry, cryptic antigen, and
bystander activation have all been proposed to explain
how viral infections may ultimately result in auto-
immunity [18, 19]. This is exemplified by the biphasic
disease induced by Theiler’s murine encephalomyelitis
virus (TMEV) [20]. Minimal clinical deficits appear dur-
ing the acute phase of TMEV infection, characterized by
neuronal infection. The protective anti-viral immune re-
sponse fails to completely eliminate infectious virus,
resulting in chronic infection of microglia and macro-
phages [21], ascending paralysis and progressive demye-
lination [22]. Whereas initial tissue destruction occurs as
a bystander effect of the anti-viral response, paralysis
and demyelination are associated with autoimmunity
mediated by SR T cells activated via epitope spreading
during chronic infection [18, 22]. TMEV infection thus
provides a paradigm for autoimmunity associated with
chronic infection and sustained inflammation. By con-
trast, demyelination induced by infections with the
neurotropic mouse hepatitis virus (MHV) strain JHM
(JHMV) or the related dual hepato- and neurotropic
strain MHV-A59 suggests that persistent CNS infec-
tions, even those associated with myelin destruction, do
not necessarily result in clinically apparent CNS auto-
immune disease. Although a vigorous CD8+ T cell- and
Th1-dominated immune anti-viral response eliminates
infectious virus [23], viral antigen and RNA persist
within the CNS without evidence of active virus replica-
tion [24, 25]. Demyelination requires both infection of
oligodendrocytes and adaptive immunity and is initiated
by T cell-mediated virus control. Similar to chronic
TMEV infection, persistent MHV infections are associ-
ated with ongoing demyelination. However, following
acute viral-induced tissue injury, sustained demyelin-
ation is balanced by myelin repair, associated with clin-
ical improvement [23, 26, 27]. The absence of disease
progression during chronic MHV infection suggests that
autoimmune responses are either not initiated or sup-
pressed. Nevertheless, during acute MHV-A59 infection,
sufficient myelin-derived self-antigen (Ag) is presented
in cervical lymph nodes (CLN) to support proliferation
of exogenously added SR T cells. However, little or no
SR T cell proliferation occurred within the CNS, suggest-
ing that T cells activated in CLN during acute infection
migrate to the CNS but are unable to promote a local
autoimmune response. The present study set out to de-
termine whether Ag-presenting cells (APC) in the CNS
support SR T cell proliferation and whether endogenous
SR T cells are induced during JHMV-induced
demyelination.
The data demonstrate that SR T cell activation is Ag-
driven and mediated by a population of CD11b+ APC
present within both the CLN- and the CNS-infiltrating
cells. Despite myelin uptake and expression of major
histocompatibility complex (MHC) class II molecules,
microglia do not support SR T cell activation. Import-
antly, the kinetics of CD11b+ cell-mediated SR T cell ac-
tivation parallels demyelination and correlated with
myelin-specific T cells derived from the endogenous host
T cell repertoire. Nevertheless, despite sustained demye-
lination and CNS inflammation, the SR T cell response
declined during viral persistence, suggesting that chronic
JHMV infection establishes an environment which




Wild-type (Wt) C57BL/6 mice were purchased from the
National Cancer Institute (Frederick, MS, USA). Myelin
oligodendrocyte glycoprotein (MOG)-specific T cell re-
ceptor (TCR) transgenic (2D2) mice expressing the con-
genic marker CD90.1 [28] were obtained from Dr. V.J.
Kuchroo (Harvard University, Boston, MA). Ovalbumine
(OVA)-specific TCR transgenic (OT-II) mice expressing
the congenic marker Ly5.1 were provided by Dr. B. Min
(Cleveland Clinic, Cleveland, OH). Mice expressing the
green fluorescent protein (GFP) under the myelin
proteolipid protein (PLP) promoter (PLP-GFP) [29] were
obtained from Dr. W.B. Macklin (University of
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Colorado, Denver, USA). All transgenic mice were bred
and maintained at the Biological Resources Unit of
the Cleveland Clinic Lerner Research Institute under
sterile conditions. All procedures were performed in
compliance with the Cleveland Clinic Institutional
Animal Care and Use Committee approved protocol
number 2013-1131.
Peptides
Peptides were obtained from Bio-Synthesis (Lewisville,




Mice were infected between 6 and 7 weeks of age in the
left hemisphere with 1000 PFU of the glia tropic JHMV
neutralizing monoclonal antibody (mAb)-derived 2.2v-1
variant [30]. Mice were assessed daily for clinical disease
severity according to the following scale: 0, healthy; 1,
hunched back and ruffled fur; 2, partial hind limb par-
alysis or inability to maintain the upright position; 3,
complete hind limb paralysis; and 4, moribund or dead.
Isolation of mononuclear cells
Anesthetized mice were perfused with phosphate-buffered
saline (PBS). Single-cell suspension was prepared from the
CLN by mechanical disruption through a 70-μm cell
strainer in RPMI 1640 medium containing 25 mM HEPES
(pH 7.2) supplemented with 10 % fetal calf serum (FCS).
Brain and spinal cord were homogenized using a Ten-
Broeck tissue grinder. Tissue homogenates were adjusted
to 30 % Percoll (Pharmacia, Uppsala, Sweden). A 1-ml
70 % Percoll underlay was added prior to centrifugation
at 850 g for 30 min at 4 °C. CNS-derived cells were
recovered from the 30–70 % interface, washed, and re-
suspended in Roswell Park Memorial Institute (RPMI)
1640 medium 10 % FCS. Splenocytes were isolated from
naïve mice by mechanical disruption and red blood cells
eliminated using Gey’s solution.
Enzyme-Linked ImmunoSpot assay
Ninety-six-well filtration plates (Millipore, Billerica, MA,
USA) were coated overnight at 4 °C with anti-inter-
feron-γ (IFN-γ) capture Ab (10 μg/ml; BD Biosci-
ences, San Diego, CA, USA). Serial dilutions of CLN-
and CNS-derived mononuclear cells pooled from a
minimum of eight mice per time point were cultured
in triplicate in RPMI complete (RPMI 1640 medium
containing 2 mM L-glutamine, non-essential amino
acid, 1 mM sodium pyruvate, 25 μg/ml gentamicin,
and 5 × 10−5 M 2-mercaptoethanol) supplement with
10 % FCS in the presence of irradiated splenocytes
(2.5 × 105 cells/well) pre-incubated with or without
1 μM peptide for 2 h at 37 °C. After 36 h at 37 °C,
spots were visualized by sequential incubation with
biotinylated anti-IFN-γ mAb (5 μg/ml; BD Biosci-
ences) overnight at 4 °C, horseradish peroxidase-
conjugated streptavidin (BD Biosciences) for 1 h at
room temperature, and 3,3′-diaminobenzidine substrate
(Sigma Aldrich, St. Louis, MO, USA). Spots were counted
using a CTL ImmunoSpot analyzer (Cellular Technology
Ltd., Shaker Heights, OH, USA). Spots detected in wells
with no stimulation (no peptide) were subtracted and re-
sults presented as the number of IFN-γ-secreting cells
normalized to 106 input cells.
Flow cytometry
Non-specific binding was blocked with mouse serum
and anti-mouse FcγIII/II mAb for 15 min on ice. Cells
were stained for surface markers for 30 min on ice using
fluorescein isothiocyanate (FITC), phycoerythrin (PE),
peridinin chlorophyll protein complex (PerCP), or allo-
phycocyanin (APC)-conjugated mAb (all from BD Bio-
sciences) specific for CD45 (clone Ly-5), CD4 (clone
GK1.5), CD8 (clone 53-6.7), CD25 (clone PC61), CD44
(clone IM7), CD45.1 (clone A20), CD90.1 (clone OX.7),
CD11b (clone M1/70), CD80 (clone 16-10A1), and
CD86 (clone GL-1). Cells were washed twice in FACS
buffer (PBS, 1 % bovine serum albumin (BSA)) prior
analysis. For proliferation study, bromodeoxyuridine
(BrdU, 1 mg/mouse) (BD Biosciences) was injected
i.p. 24 h prior to sacrifice. Mononuclear cells from
CLN and CNS were prepared as described above,
stained for surface markers followed by intracellular
BrdU according to the manufacturer’s instructions
using the FITC BrdU flow kit (BD Biosciences). Data
were analyzed using a FACSCalibur flow cytometer
(BD Biosciences) and FlowJo software (Tree Star Inc.,
Ashland, OR, USA).
Isolation of naïve CD4+ T cells and adoptive transfer
CD4+ T cells were enriched from naïve 2D2 (TCR trans-
genic mice specific for MOG35-55) or OT-II (TCR trans-
genic mice specific for OVA) mice by negative selection
using the CD4+ T cell isolation kit II (Miltenyi Biotec
Inc., Auburn, CA, USA), according to the manufacturer
instructions. Naïve (CD25−CD44lo) CD4+ T cells were
then purified by cell sorting (FACSAria, BD Biosciences).
Sub-lethally irradiated (450 rad) Wt recipients received
equal numbers (106 cells) of purified naïve OT-II and
2D2 CD4+ T cells by intravenous injections and were
challenged with virus 2 weeks after adoptive transfer.
Isolation of antigen-presenting cells and proliferation
analysis
CLN, brains, and spinal cords were isolated at various
times post-infection (p.i.) from PBS-perfused mice. CLN
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were mechanically disrupted through a 70-μm cell
strainer as described above, whereas brains and spinal
cords were finely minced with a razor blade. Suspensions
were digested in RPMI 1640 medium containing 10 %
FCS, 0.5 % collagenase (100 mg/ml) (Roche, Basel,
Switzerland), and 1 % DNase I (1 mg/ml) (Sigma
Aldrich) for 40 min at 37 °C. Collagenase was then
inactivated by addition of 1 % 0.1 M EDTA for 5 min at
37 °C. Following centrifugation at 400 g for 7 min at 4 °C,
CLN-derived cells were directly resuspended in FACS buf-
fer for staining, whereas CNS-derived cells were isolated
using Percoll gradients prior to staining as described
above. CLN-derived CD11b− and CD11b+ cells, CNS-
infiltrating CD45hiCD11b+, microglia (CD45loCD11b+),
and CD45hiCD11b− cells were purified using a cell sorter
(FACSAria) and resuspended in RPMI complete 10 %
FCS. Naïve CD4+ T cells were purified from splenocytes of
naïve 2D2 mice using the CD4+CD62L+ T cell isolation kit
II (Miltenyi Biotec) according to the manufacturer instruc-
tions. Naïve 2D2 CD4+ T cells were then stained with car-
boxyfluorescein succinimidyl ester (CFSE, 1.25 μM)
(Molecular Probes, Carlsbad, CA, USA) and cultured in a
96-well plate in the presence of CLN-derived CD11b− or
CD11b+ cells, CNS-derived CD11b− or CD11b+ cells, or
microglia (T cells/APC ratio 1:1) in RPMI complete 10 %
FCS for 4 days at 37 °C. Rat anti-MHC class II blocking
mAb (clone M5/114) (Abcam, Cambridge, MA) or
MOG35-55 peptide (10 μM) were added at the initiation of
the cultures for some experiments. T cell proliferation was
assessed by measuring the percentage of CFSE dilution by
flow cytometry.
Immunofluorescence
Mice were perfused with ice-cold PBS followed by 4 %
paraformaldehyde (PFA). Spinal cords were dissected,
fixed for 1 h in 4 % PFA at 4 °C, and then incubated with
sucrose gradients as follows: 30 min with 15 % sucrose at
room temperature, 30 min with 20 % sucrose at 4 °C, and,
finally, overnight with 30 % sucrose at 4 °C. Tissues were
stored in cryoprotection solution until preparation of 30-
μm microtome sections. After antigen retrieval with
0.01 M sodium citrate buffer pH 6.0, sections were treated
with 1 % Triton X-100 for 30 min, treated with blocking
solution (PBS, 1 % BSA, 10 % normal goat serum) for
30 min, and stained with rabbit anti-mouse Iba1 (Wako,
Richmond, VA) and mouse anti-mouse PLP (Millipore)
primary mAbs overnight at 4 °C. Alexa Fluor 488 goat
anti-rabbit (Invitrogen, Carlsbad, CA) and Alexa Fluor
594 goat anti-mouse (Invitrogen) were added for 1 h at
room temperature. Sections were mounted with Vecta-
shield mounting medium with 4′-6-diamidino-2-pheny-
lindole (DAPI) (Vector Laboratories) and analyzed using a
Leica TCS confocal microscope.
Data analysis
Results represent the mean ± SEM and are plotted using
GraphPad Prism software. Statistics were calculated
using a two-tailed unpaired Student’s t test, ANOVA
with Bonferroni post-test, and Dunn’s multiple compari-
son test, and p values <0.05 were considered statistically
significant.
Results
Activation and CNS recruitment of SR CD4+ T cells
Infection with the MHV-A59 strain suggested that acute
encephalomyelitis provides a milieu capable of support-
ing proliferation of transferred MOG-specific T cell re-
ceptor (TCR) transgenic T cells within the CLN [31].
However, neither their reactivation within the CNS, pro-
longed survival, or potential to induce autoimmunity
have been explored. To determine whether SR CD4+ T
cells are retained during chronic infection, MOG-
specific 2D2 CD4+ T cells were transferred to sub-
lethally irradiated Wt mice prior to JHMV infection. By
enhancing engraftment of donor T cells, this approach
increased SR T cells to numbers amenable to flow cyto-
metric analysis, while maintaining a host anti-viral im-
mune response. Bone marrow-derived inflammatory
(CD45hi) cells were minimal within the CNS of recipi-
ents prior to infection (Fig. 1a), indicating non-specific
activation and that CNS recruitment was prevented by
intact blood brain barrier. At day 7 p.i., maximal anti-
viral T cell responses [24, 25] coincided with a decreased
percentage of transferred SR T cells in CLN (Fig. 1b, c).
Grafted SR T cells were undetectable within the CNS at
day 7 p.i. following JHMV infection (Fig. 1b, c) in con-
trast to their early migration into the CNS during acute
MHV-A59 infection [31]. Nevertheless, transferred SR T
cells were present in the CNS of JHMV-infected mice by
day 14 p.i. (Fig. 1b, c); furthermore, similar proliferation
of grafted SR T cells and host CD4+ T cells suggested
identical activation (Fig. 1d). Although the kinetics dif-
fered, these data are consistent with CNS recruitment of
SR T cells during MHV-mediated demyelination, inde-
pendent of the virus strain and tropism [31]. Import-
antly, retention of transferred SR T cells at slightly
declining frequencies within the total CNS CD4 popula-
tion out to day 30 p.i. (Fig. 1b, c) negated preferential ex-
pansion/survival during chronic viral infection. The
absolute numbers of grafted SR CD4+ T cells gradually
declined (Fig. 1c) concomitant with contraction of the
overall CD4+ T cell population, supporting a lack of on-
going self-Ag-driven survival. Furthermore, retention of
SR T cells within the CNS did not alter disease severity
out to 30 days p.i. (Fig. 1e). Within the CLN, transferred
SR T cells comprised ~40 % of activated CD44hi cells
(data not shown) and their absolute numbers remained
stable during ongoing chronic JHMV infection (Fig. 1c).
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Fig. 1 Peripheral activation and CNS recruitment of self-reactive CD4+ T cells is myelin driven. a Irradiated Wt mice received 1 × 106 naïve MOG-
specific 2D2 (CD90.1+) CD4+ T cells i.v. Two weeks post-transfer and prior infection, CD45hi cells within the CNS were analyzed by flow cytometry
and compared to age-matched non-irradiated Wt mice. b Representative FACS density plots of 2D2 cells within CD4+ T cells isolated from the
CNS and CLN at days 0, 7, 14, 21, and 30 p.i. c Frequency and absolute number of 2D2 cells within CD4+ T cells in the CNS and CLN at days 0, 7, 14,
21, and 30 p.i. Data represent the mean of three individual mice per time point. d Frequencies of proliferating host CD90.1−CD4+ and transferred
CD90.1+CD4+ T cells within the CNS and CLN, characterized by BrdU incorporation and analyzed by flow cytometry. Data represent the mean ± SEM of
three individual mice. e Mean clinical scores following JHMV infection of WT mice without transfer (n = 15) or following 2D2 T cell
transfer (n = 32). f Irradiated Wt mice received 1 × 106 MOG-specific 2D2 (CD90.1+) CD4+ T cells and an equal number of OVA-specific
OT-II (Ly5.1+) CD4+ T cells. Percentages of CD90.1+ 2D2 and Ly5.1+ OT-II cells within the CLN before infection (d0) and in both the CLN
and CNS at day 14 p.i. Bar graphs represent the mean ± SEM of two separate experiments
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Limited proliferation of SR T cells within the CNS dur-
ing acute MHV-A59 infection [31] suggested the possi-
bility of non-specific T cell recruitment. To determine
the specificity of recruitment into the CNS, heterologous
OVA-specific T cells were co-transferred with SR T cells
to sub-lethally irradiated mice. Prior to infection, the fre-
quencies of both the SR- and OVA-specific T cells were
similar in CLN (Fig. 1f ) and blood (data not shown),
demonstrating equivalent survival. Following JHMV in-
fection, the relative percentages of both the SR- and
OVA-specific T cells were reduced in the CLN coinci-
dent with the expansion of virus-specific T cells. How-
ever, the decline in transferred SR T cells was less
dramatic, suggesting enhanced survival cues via Ag-
specific activation (Fig. 1f ). Consistent with an absence
of non-specific peripheral activation, OVA-specific T
cells were not detected in the inflamed CNS at day 14
p.i. By contrast, transferred SR T cells constituted a
discrete population (Fig. 1f ), confirming migration of
peripherally activated cells and supporting Ag-
dependent CNS retention of SR CD4+ T cells.
SR T cell activation by CD11b+ cells in CLN
CLN constitute the major site of peripheral lymphoid
drainage from the CNS [32, 33]. This is supported by ac-
tivation of JHMV-specific T cells within the CLN [34]
and detection of myelin antigens in MS patients and ro-
dents with experimental autoimmune encephalomyelitis
(EAE) [35–37], as well as following demyelination in-
duced by oligodendrocyte death [38]. Myelin, either in a
soluble form or associated with APC, drains to CLN,
where it can potentially activate naïve SR T cells [36, 39]
via presentation by CD11b+ cells, comprising both den-
dritic cells (DC) and macrophages [40]. During EAE, the
most efficient population-presenting myelin antigen in
the CNS is CD11b+CD11c+ [41, 42]. CD11b+ cells repre-
sent a small subset (between 2.5 and 4 %) of the CLN
population, which only varies slightly throughout the
course of JHMV infection (Fig. 2a). Importantly, CD11c+
cells constitute the vast majority of CD11b+ cells
(~70 %) and their frequencies within the CD11b+ popu-
lation remain constant between days 7 and 30 p.i.
(Fig. 2a). We therefore tested unfractionated CLN-
derived CD11b+ cells for the presentation of self-Ag fol-
lowing JHMV infection. CD11b+ and control CD11b−
cells were purified from the CLN at different times p.i.
and were co-cultured with CFSE-labeled MOG-specific
CD4+ T cells as a source of SR T cells. Neither CD11b+
nor CD11b− cells isolated at day 7 p.i. supported SR T
cell activation (Fig. 2c). However, by day 10 p.i., when
myelin damage becomes apparent, both CD11b+ and
CD11b− cells initiated minimal T cell proliferation,
which reached statistical significance relative to un-
stimulated conditions (no APC) for CD11b+ cells
(Fig. 2c). Activation of SR T cells by the CD11b+ popula-
tion increased at days 14 and 21 p.i. concomitant with
enhanced demyelination [23, 43], while the CD11b−
population retained only a minimal ability to support SR
T cell proliferation (Fig. 2b, c). The ability of CLN-
derived CD11b+ cells to support SR T cell proliferation
declined, but was sustained, by day 30 p.i., while the
minimal ability of the CD11b− population dropped to
below detection by 30 days p.i. (Fig. 2c). The presence of
myelin Ag within the CLN by day 14 p.i. supports the
possibility that endogenous SR T cells could be activated
following JHMV-induced demyelination.
CNS-infiltrating myeloid cells support SR CD4+ T cell
responses
The absence of clinically apparent autoimmunity, coinci-
dent with a decline rather than progressive increase in
SR T cells in the CNS during chronic JHMV infection
(Fig. 1c), suggested that SR T cells fail to be continuously
reactivated within the CNS. In the inflamed CNS, resi-
dent microglia and myeloid cells constitute heteroge-
neous populations of APC potentially capable of
presenting self-Ag [40]. To determine whether CNS-
infiltrating myeloid cells, comprising macrophages and
dendritic cells, and/or microglia are capable of process-
ing and presenting self-Ag within the CNS following in-
fection, both potential APC populations were purified
based on differential CD45 expression [44, 45] at distinct
times p.i. and tested for the ability to support SR T cell
activation in the absence of exogenously added Ag. Infil-
trating myeloid cells at day 7 p.i. (Fig. 3a) were com-
prised of ~30 % CD11c+ cells, a proportion that
gradually increased during the course of infection to
reach ~55 % at day 30 p.i. (Fig. 3a). At the peak of acute
inflammation (day 7 p.i.), neither the CD45hiCD11b+,
CD45hiCDllb−, nor microglia populations supported T
cell proliferation (Fig. 3c). However, SR T cell prolifera-
tion was modestly increased by the CD11b+ APC subset
at day 10 p.i. (Fig. 3c) and prominently by day 14 p.i.
(Fig. 3b, c), similar to the CLN (Fig. 2). On a per cell
basis, the ability of infiltrating CD11b+ cells to support
proliferation remained relatively stable during chronic
JHMV infection (Fig. 3c). Although CD11b− cells ap-
peared to promote minimal proliferation, their activity
remained near threshold levels throughout the infection.
Similar to the CD11b− population, microglia were un-
able to support SR T cell proliferation at any time p.i.
(Fig. 3b, c). The kinetics of SR CD4+ T cell activation by
CNS-infiltrating CD11b+ cells correlate with viral-
induced myelin destruction as a source of self-Ag [43].
In addition, anti-MHC class II Ab blocked proliferation,
supporting MHC class II-dependent T cell activation
(Fig. 3d) rather than non-specific proliferation signals
derived from the inflamed CNS environment (Fig. 1d).
Savarin et al. Journal of Neuroinflammation  (2015) 12:207 Page 6 of 15
MHC class II expression was compared on microglia
and infiltrating CD11b+ cells by flow cytometry to exam-
ine whether the inability of microglia to support T cell
proliferation correlated with differential MHC class II
expression. While no differences were noted in the
percentage of class II-expressing cells within the
populations (Fig. 4a), microglia were inferior to infiltrat-
ing CD11b+ cells in their level of class II expression
based on MHC class II mean fluorescence intensity
(MFI) (Fig. 4a), even at the peak of IFN-γ release at day
7 p.i. [25]. Similarly, the MFI of the co-stimulatory mol-
ecule CD86 was slightly lower on microglia compared to
Fig. 2 CLN-derived CD11b+ cells activate MOG-specific CD4+ T cells. a Percentages of CD11b+ cells and CD11c+ cells within the CD11b+ population in
the CLN from days 7 to 30 p.i. b Representative CFSE dilution gated on 2D2 CD90.1+CD4+ T cells 4 days after co-culture with media only (No APC),
CLN-derived CD11b−, and CD11b+ cells at day 14 p.i. c Percentages of proliferating 2D2 cells co-cultured with media only (No APC), CD11b−, and
CD11b+ cells isolated from the CLN of JHMV-infected mice at days 7, 10, 14, 21, and 30 p.i. Data represent the mean ± SEM with n = 3–12 pooled mice
per time point from three separate experiments. #p < 0.05 and ###p < 0.001 depict significant differences between No APC and CD11b+ cells, whereas
§§§p < 0.001 depicts significant differences between CD11b− and CD11b+ cells determined by a two-way ANOVA with Bonferroni post-test. Significant
differences between time points are indicated by **p < 0.01 and ***p < 0.001 using Dunn’s multiple comparison test
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infiltrating CD11b+ cells, while no differences were ob-
served for CD80 expression levels (Fig. 4b). Moreover,
while MHC class II expression was sustained at similar
levels on microglia, it was further upregulated between
day 14 and 21 p.i. on infiltrating CD11b+ cells (Fig. 4a).
To assess whether myelin Ag added to the cell culture
could overcome the inability of microglia to activate SR
T cells, CD11b+ APC populations were pre-incubated
with MOG peptide. Under these conditions, microglia
induced proliferation of SR CD4+ T cells as well as infil-
trating CD11b+ cells (Fig. 4c). These data demonstrate
that while class II levels on microglia suffice to present
Fig. 3 CNS-derived CD45hiCD11b+ cells present endogenous myelin antigen. a Numbers of CD45hiCD11b+ cells and frequencies of CD11c+ cells
within CD45hiCD11b+ populations in the CNS at days 7 to 30 p.i. b Representative CFSE dilution gated on 2D2 CD90.1+CD4+ T cells 4 days after
co-culture with media only (No APC), CD45hiCD11b−, CD45hiCD11b+ cells, and microglia (CD45lowCD11b+) purified from the CNS at day 14 p.i. c
Percentages of proliferating 2D2 T cells co-cultured with media only (No APC), CD45hiCD11b−, CD45hiCD11b+ and CD45lowCD11b+ cells purified
from the CNS between days 7 and 30 p.i. Data represent the mean ± SEM from at least four separate experiments with n = 7 pooled mice per time
point per experiment. #p < 0.05, ##p < 0.01, ###p < 0.001 depict significant differences between No APC and CD45hiCD11b+ cells, whereas §§§p < 0.001
depicts significant differences between CD45hiCD11b− and CD45hiCD11b+ cells and ¶p < 0.05 and ¶¶p < 0.01 depict significant differences between
CD45lowCD11b+ and CD45hiCD11b+ cells at a given time point, determined by a two-way ANOVA with Bonferroni post-test. Significant
differences between time points are indicated *p < 0.05 using Dunn’s multiple comparison test. d Proliferation of 2D2 CD4+ T cells co-
cultured with CD45hiCD11b+ isolated from the CNS at day 14 p.i. with or without anti-MHC class II blocking antibody
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exogenous myelin peptide to activate cognate T cells,
only infiltrating CD11b+ cells act as APC of endogenous
myelin Ag to SR T cells; importantly, this capacity is
retained throughout chronic infection.
The inability of microglia to support SR T cell prolifer-
ation may reflect a defect in myelin uptake or Ag pro-
cessing. Myelin engulfment by Iba1+ cells supports
myelin uptake by microglia and/or infiltrating myeloid
cells during JHMV-induced demyelination (Fig. 5a).
However, the amoeboid morphology of microglia during
inflammation prevents histological distinction between
myelin in macrophages versus microglia (Fig. 5a). Mice
expressing GFP under the PLP promoter were therefore
infected to quantify GFP as a surrogate marker for mye-
lin ingestion by infiltrating CD11b+ cells versus micro-
glia. Flow cytometry revealed GFP within both
infiltrating myeloid cells (CD45hiCD11b+) and microglia
(CD45lowCD11b+) (Fig. 5b, c). Percentages of infiltrating
myeloid cells and microglia containing GFP were rela-
tively stable between days 7 and 30 p.i. (Fig. 5b), with a
Fig. 4 MHC class II expression and exogenous myelin antigen presentation by CNS-infiltrating CD11b+ cells and microglia. a Percentage and
mean fluorescence intensity (MFI) expression of MHC class II by CNS-derived control (CD45hiCD11b−), infiltrating CD11b+ (CD45hiCD11b+), and
microglia (CD45lowCD11b+) cells between days 7 and 30 p.i. Data represent the average ± SEM of three separate experiments with n = 3 pooled
mice per experiment. Histogram of MHC class II expression by CD45hiCD11b− (black line), infiltrating CD11b+ (red line), and microglia (blue line)
during JHMV infection. b MFI expression of CD80 and CD86 by CNS-infiltrating CD11b+ (CD45hiCD11b+) and microglia (CD45lowCD11b+) cells
between days 7 and 30 p.i. Data represent the average ± SEM of 3 separate experiments with n = 3 pooled mice per experiment. c Proliferation of
2D2 CD4+ T cells co-cultured with CD45hiCD11b+ and CD45lowCD11b+ cells with or without exogenously added MOG35-55 peptide
Savarin et al. Journal of Neuroinflammation  (2015) 12:207 Page 9 of 15
higher proportion of microglia containing GFP, support-
ing their primary role in demyelination [46]. In contrast
to percentages, MFI analysis showed that the amount of
GFP differed throughout the course of infection (Fig. 5c).
Infiltrating CD11b+ cells exhibited peak uptake at 14 days
p.i., which slowly decreased at later time points (Fig. 5c),
but remained higher than GFP MFI in the control
CD45hiCD11b− population, as well as CD45hiCD11b+
cells isolated from naïve animals (Fig. 5c). By contrast, a
gradual increase in GFP was observed within microglia
throughout the course of JHMV infection independent
of auto-fluorescence (Fig. 5c). These data imply that
both the infiltrating myeloid and microglial popula-
tions phagocytoze myelin during viral-induced demye-
lination. Therefore, the inability of microglia to
support SR T cell activation is less likely to reside in
Fig. 5 Myelin debris within CNS cells. a PLP (red) and Iba1 (green) stainings on spinal cord tissue isolated from Wt-infected mice at day 21 p.i. and
analyzed by confocal microscopy. Scale bar, 10 μm. (i) 3D reconstruction image view, yz (ii), and xz (iii) projections show PLP+ myelin in close contact
and engulfed (arrow head) by Iba1+ cells. b Percentage of CD45hiCD11b+ and microglia (CD45lowCD11b+) containing GFP between days 7
and 30 p.i. during infection of PLPGFP mice. c Mean GFP fluorescent intensity (MFI) analyzed by flow cytometry in CNS-infiltrating
CD45hiCD11b− and CD45hiCD11b+ cells and microglia (CD45lowCD11b+) between days 0 to 30 p.i. Hashed bars represent microglia auto-
fluorescence detected within infected Wt mice between days 7 and 30 p.i. Data represent the mean ± SEM from two separate
experiments with n = 3 per time point per experiment
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a defect in myelin uptake, rather than inefficient Ag
processing and/or presentation.
SR T cells within the CNS during chronic viral infection
Myelin damage, uptake and subsequent presentation of
self-Ag by potential APC, and sustained CNS inflamma-
tion without overt clinical evidence of autoimmune dis-
ease following JHMV infection pose a dilemma.
Plausible explanations may be that SR T cells are either
not, or only minimally, induced or that they are not
reactivated within the CNS. Indeed, demyelination trig-
gered by oligodendrocyte death fails to initiate auto-
immunity, despite myelin Ag drainage to CLN [38]. To
determine if JHMV-induced demyelination results in the
activation of endogenous SR T cells, CD4+ T cell re-
sponses to the H-2b restricted encephalitogenic myelin
epitopes MOG35-55 and MBP60-80 were assessed by
Enzyme-Linked ImmunoSpot (ELISPOT) to detect low-
frequency responder cells. Responses to the H-2b-re-
stricted immuno-dominant viral M133 epitope [47] were
used as positive controls. Analysis focused on IFN-γ-
producing CD4+ T cells, as JHMV infection induces a
vigorous Th1 response with negligible IL-17 or IL-9
components (data not shown), which is supported by no
affects on pathogenesis in the absence of IL-23 [48].
Virus- as well as myelin-specific T cell frequencies were
lower than 9 and 5 positive cells per 106, respectively,
within the CLN and spleen of naïve animals (Fig. 6a).
Within CLN, the frequency of virus-specific CD4+ T
cells peaked at day 7 p.i., declined by day 14 p.i., and
remained relatively stable up to day 60 p.i. (Fig. 6a).
Within the CNS, frequencies of virus-specific T cells
were ~10 higher than CLN at day 7 p.i., continued to in-
crease at day 14 p.i., and declined as the overall inflam-
matory response resolved due to virus control (Fig. 6a).
SR T cells specific for both the immuno-dominant
MOG and myelin basic protein (MBP) epitopes within
the CLN were above baseline throughout acute and
chronic JHMV infection, albeit at very low frequencies
(Fig. 6a). Maximum SR T cell frequencies were observed
at day 30 p.i. (Fig. 6a) with responses near detection
limits in a large proportion of infected mice throughout
infection (Fig. 6b). A very limited number of infected
mice harbored SR T cells within the CNS during acute
infection at days 7 and 14 p.i. However, by day 21 p.i.,
the number of responder mice exhibiting SR T cells
within the CNS reached 100 % (Fig. 6b), coincident with
peak frequencies of both MOG- and MBP-specific T
cells between days 21 and 30 p.i. (Fig. 6a). These data
are consistent with maximal clinical disease throughout
days 14–21 p.i. in all infected mice (Fig. 6c). Although
the SR T cell frequencies in the CNS were variable
among individual mice, and always reduced relative to
virus-specific T cells, they were increased relative to the
CLN at day 21 p.i. and thereafter (Fig. 6a). Importantly,
CNS SR T cells were sustained above baseline during
resolution of clinical symptoms, with preferential stabil-
ity of MOG-specific T cells (Fig. 6a, b). However, com-
pared to peak SR T cell frequencies at days 21/30 p.i.,
frequencies, as well as the number of mice harboring
CNS SR T cells, declined as clinical disease resolved
(Fig. 6c). These data demonstrate that endogenous SR T
cells are induced in the vast majority of JHMV-infected
mice. However, they are only sustained within the CNS
of ~60 % of mice during chronic demyelination, when le-
sion formation is counterbalanced by repair (Fig. 6a, b).
Importantly, segregation of mice harboring SR T cells
within the CNS after day 30 versus mice in which SR
T cells were undetectable showed no differences in
overall clinical recovery (Fig. 6d). These data further
supported our previous observations that CNS re-
cruitment and retention of SR T cells did not alter
disease severity (Fig. 1e).
Discussion
Animal models have demonstrated that viral infections
can promote the initiation as well as increase the sever-
ity of autoimmune diseases [4]. However, evidence for a
viral etiology of human autoimmune diseases, including
MS, remains elusive. Moreover, given the extent of both
acute and persisting viral infections without evidence of
autoimmune sequelae, it has also been proposed that in-
fections may even provide protection from autoimmun-
ity. Specifically, the conditions promoting or stemming
activation of auto-Ag-specific T cells following viral-
induced tissue damage have not been extensively ex-
plored. Chronic CNS infection by the naturally occur-
ring mouse pathogen TMEV promotes activation of SR
T cells, which mediates increasing tissue destruction ac-
companied by an ascending paralysis [20]. By contrast,
infection with JHMV also leads to immune-mediated de-
myelination; however, persistent infection correlates with
clinical recovery [27]. While clinical improvement
throughout persistence despite ongoing demyelination
supported the absence of an autoimmune component
following neurotropic MHV infection, previous studies
clearly demonstrate sufficient auto-Ag presentation to
induce SR T cell responses [31, 49, 50]. In an effort to
reconcile peripheral activation of SR T cells, but no dis-
ease exacerbation, this study set out to assess kinetics of
auto-Ag presentation as well as the fate of SR T cells fol-
lowing JHMV infection. The data demonstrate the pres-
ence of APC capable of activating SR T cells in both the
CLN and the CNS with maximal stimulating activity
during the time of most overt demyelination. While both
the CNS-infiltrating myeloid population and microglia
ingest GFP as a surrogate for myelin, only the CNS-
infiltrating APC were capable of presenting endogenous
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Fig. 6 Myelin-specific CD4+ T cell activation following JHMV infection. a Number of virus-specific M133, MOG35-55-specific, and MBP60-80-specific
CD4+ T cells per 106 cells in the CLN and CNS of JHMV-infected mice between days 7 to 60 p.i. Each dot represents the triplicates of individual
experiments at various dilutions of at least eight pooled mice. Dashed lines represent the limit of detection determined as frequencies of IFN-γ-
secreting cells specific for M133, MOG35-55, and MBP60-80 detected in naïve animals. Red bars represent the mean ± SEM. Significant differences
between time points are indicated *p < 0.05, **p < 0.01, and ***p < 0.001. Significant differences compared to baseline levels are indicated #p <
0.05, ##p < 0.01, and ###p < 0.001 using unpaired t test. b Percentage of mice exhibiting IFN-γ-secreting MOG and MBP-specific CD4+ T cells
above maximal baseline levels in the CLN and CNS between days 7 and 60 p.i. c Clinical symptoms following JHMV infection. Data represent the
mean ± SEM of 32 mice. d Correlation between frequencies of SR T cells at days 45 and 60 p.i. with average clinical scores, coefficient of
determination R2 = 0.1417
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myelin Ag to SR T cells ex vivo. Finally, the results dem-
onstrate that SR T cells are activated from the endogen-
ous T cell repertoire when myelin destruction is evident,
but infectious virus is already controlled. Although SR T
cells migrate into and are most prominent in the persist-
ently infected CNS during maximal demyelination, no
evidence was found to suggest preferential expansion
despite ongoing demyelination, consistent with minimal
re-stimulation in vivo.
Mechanisms underlying SR T cell activation following
CNS infections include molecular mimicry between
pathogen and self-epitopes, presentation of self-peptides
from tissue damage, and dysregulation of regulatory
tolerance mechanisms [51, 52]. Myelin-specific T
cells isolated from MS patients have been shown to
cross-react with human coronavirus [53, 54]. Simi-
larly, homology was found between MHV and myelin
peptides, potentially triggering autoimmune disease
[55]. Nevertheless, SR T cells were near detection
levels within the CNS during acute JHMV infection
in the vast majority of mice and their frequency only
increased as myelin damage increased. Moreover,
their numbers declined as clinical symptoms dropped
due to increased repair. Self-Ag-specific activation of
SR T cells is further supported by the lack of T cell
activation with irrelevant specificity and blockade of
activation by anti class II Ab, ruling out bystander
events. Overall, our data support the hypothesis that
release of myelin debris due to JHMV-induced tissue
damage results in cell-free or cell-associated myelin
drainage to CLN, where a population of CD11b+
APC can support the activation of SR T cells. Acti-
vated SR T cells access the CNS at a time when the
vast majority of infectious virus is already controlled,
but persistence drives ongoing expression of proin-
flammatory molecules capable of recruiting activated
cells from circulation [56]. Local encounter with
myelin-loaded CD45hiCD11b+ APC, but not micro-
glia, is then poised to drive SR T cell reactivation.
The apparent inability of microglia to activate SR
CD4+ T cells ex vivo remains unclear as their uptake
of myelin is consistent with demyelination independ-
ent of inflammatory monocyte recruitment following
JHMV infection [46]. Nevertheless, microglia also
failed to support CD4+ T cell responses following
TMEV infection and induction of EAE [57, 58]. In
fact, several studies question the role of microglia as
APC in vivo [59] despite their implication as APC
based on expression of MHC class II and co-
stimulatory molecules in both MS patients [60] and
EAE [61], as well as their ability to activate CD4+ T
cells in vitro [57]. Detection of myelin within Iba1+
cells increased GFP MFI in microglia, as well as
detection of myelin in microglia in other models
[57, 58] supports self-Ag uptake during JHMV infec-
tion. However, these data suggest that microglia may
be poor at processing myelin Ag for loading onto
MHC class II. This notion is also supported by ef-
fective priming of SR T cells using exogenous pep-
tide, despite reduced MHC class II expression
relative to infiltrating CD11b+ cells. In addition, as
activated microglia can adapt to their surroundings
to mediate both pro- and anti-inflammatory func-
tions [62], it cannot be excluded that microglia may
negatively regulate SR T cell responses during
chronic JHMV infection by limiting T cell prolifera-
tion or by inducing apoptosis [63].
The results also indicate a discrepancy between
APC presentation capacity ex vivo, yet apparently lim-
ited SR T cell activation in vivo. Although APC in
CLN sustain their ability to activate SR T cells
throughout days 14 to 30 p.i., endogenous SR T cells
are only detected at low frequencies and exhibit a
brief peak at day 30 p.i. Maximal accumulation of SR
T cells in the CNS between days 21 and 30 p.i. in all
mice supports efficient egress from CLN. Whether
frequencies in the CNS are supported by ongoing re-
cruitment or local expansion remains unclear. The
capacity of CNS-infiltrating CD11b+ cells to activate
SR T cells ex vivo in the absence of exogenous pep-
tide indicates that APC are competent to reactivate
SR T cells throughout chronic infection. However, no
evidence for preferential expansion or retention of SR
T within the CNS relative to virus-specific CD4+ T
cells suggests that the absence of sustained activation
may contribute to the lack of increasing clinical
symptoms during chronic infection. These results
clearly differ from the TMEV model, in which SR T
cells aggravate pathology and clinical disease. One
possible scenario is that persistent JHMV infection
may establish an environment that suppresses the SR
T cell response. JHMV infection induces both Ag-
specific and Foxp3+ regulatory T cells [64, 65] which
are efficient at controlling autoimmunity in other set-
tings [66, 67]. Treg depletion [65], elimination of Ag-
specific Treg [65], and adoptive transfer of Foxp3+
Treg [68] during acute JHMV infection all demon-
strated that, in contrast to TMEV [69], Tregs have a
limited effect on virus clearance. Nevertheless, Foxp3+
Tregs play a critical role in limiting tissue destruction
[68], suggesting that they regulate the activation or
effector function of SR T cells following JHMV-
induced demyelination [70]. Although Treg control of
SR T cells in vivo and their association with increased
tissue destruction remains unknown, depletion of
Treg correlates with increased proliferation of SR T
cells in the CLN during acute MHV-A59 infection
[31]. Whether Tregs act in limiting SR T cell
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induction during JHMV infection, which does not or
only poorly replicates in CLN, or whether additional
factors limit SR T cell responses at the target site re-
mains to be elucidated.
Conclusions
This study demonstrates the activation and kinetics of
SR CD4+ T cells within the endogenous T cell repertoire
relative to self-Ag presentation by APC following
JHMV-induced demyelination. Importantly, ongoing
myelin loss, sustained CNS-derived APC activity ex vivo,
and retention of SR T cells do not lead to autoimmune
disease during chronic JHMV infection. This model thus
provides a unique opportunity to determine mechanisms
preventing autoimmunity in the context of a persistent
viral infection.
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